A 58-year-old client with cirrhosis presents with hematemesis and a hemoglobin of 6.8 g/dL. The prescriber orders an octreotide 50 mcg IV bolus followed by 50 mcg/hour continuous infusion. Which monitoring parameter is most important during therapy?

Octreotide is a synthetic somatostatin analogue used for acute variceal bleeding (vasoconstriction of splanchnic vessels reduces portal pressure), severe diarrhea (carcinoid, VIPoma, dumping syndrome, chemotherapy-induced), acromegaly, and pituitary tumor adjunctive therapy. In acute variceal bleeding it is given as a 50 mcg IV bolus followed by 50 mcg/hour continuous infusion typically for 3 to 5 days alongside endoscopic band ligation, broad-spectrum antibiotics, and packed RBC support. Key monitoring during infusion: (1) heart rate and rhythm because bradycardia and arrhythmia are common; (2) blood pressure because hypotension or hypertension can occur; (3) fingerstick glucose because somatostatin suppresses both insulin and glucagon and can produce either hypoglycemia or hyperglycemia depending on the patient — diabetics are at particular risk; (4) abdominal pain, RUQ tenderness, jaundice, or fatty stools suggesting biliary stasis, gallstone formation, or pancreatitis; (5) GI symptoms (nausea, cramping, steatorrhea) and rarely bowel ischemia; (6) injection site reaction with SC dosing; (7) signs of ongoing bleeding (hematemesis, melena, hemodynamics, hemoglobin trend) to assess effectiveness. Capillary refill, daily weight, and temperature alone miss the cardiometabolic and biliary surveillance that drive nursing decisions during the infusion.

Octreotide affects multiple endocrine and GI axes — cardio (HR, BP), metabolic (glucose), and biliary surveillance are the cluster the NCLEX rewards. Always assess effectiveness via the bleeding source as well.